[HTML][HTML] Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis
CW Nugroho, SD Suryantoro, Y Yuliasih… - …, 2021 - ncbi.nlm.nih.gov
Background: Several studies have revealed the potential use of tocilizumab in treating
COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab
may provide clinical benefits for cytokine release syndrome in COVID-19 patients. Methods:
We searched for relevant studies in PubMed, Embase, Medline, and Cochrane published
from March to October 2020 to evaluate optimal use and baseline criteria for administration
of tocilizumab in severe and critically ill COVID-19 patients. Research involving patients with …
COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab
may provide clinical benefits for cytokine release syndrome in COVID-19 patients. Methods:
We searched for relevant studies in PubMed, Embase, Medline, and Cochrane published
from March to October 2020 to evaluate optimal use and baseline criteria for administration
of tocilizumab in severe and critically ill COVID-19 patients. Research involving patients with …
[PDF][PDF] Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis [version 1; peer review
Background: Several studies have revealed the potential use of tocilizumab in treating
COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab
may provide clinical benefits for cytokine release syndrome in COVID-19 patients. Methods:
We searched for relevant studies in PubMed, Embase, Medline, and Cochrane published
from March to October 2020 to evaluate optimal use and baseline criteria for administration
of tocilizumab in severe and critically ill COVID-19 patients. Research involving patients with …
COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab
may provide clinical benefits for cytokine release syndrome in COVID-19 patients. Methods:
We searched for relevant studies in PubMed, Embase, Medline, and Cochrane published
from March to October 2020 to evaluate optimal use and baseline criteria for administration
of tocilizumab in severe and critically ill COVID-19 patients. Research involving patients with …
以上显示的是最相近的搜索结果。 查看全部搜索结果